Debiopharm and GPC Biotech to partner in small molecule antagonists programme

Published: 17-Dec-2004

For GPC Biotech\'s preclinical small molecule MHC class II antagonists programme


Swiss drug development company Debiopharm and GPC Biotech, of Germany, have signed a license agreement for GPC Biotech's preclinical small molecule MHC class II antagonists programme.

Under the agreement, Debiopharm is licensing the exclusive worldwide rights to GPC Biotech's programme for further development and will assume all future development costs. GPC Biotech will receive an upfront payment, milestone payments and royalties. Further financial details were not disclosed.

'This programme offers an immense potential in chronic autoimmune diseases and our objective is to rapidly prove this concept and bring a meaningful new treatment to patients,' said Rolland-Yves Mauvernay, president and ceo of Debiopharm.

Dr Bernd R. Seizinger, ceo of GPC Biotech added: 'While GPC Biotech has focused its internal development efforts on oncology, the partnering of this programme also shows the value of our earlier research in other indications such as autoimmune diseases. There still is no treatment available that addresses the cause of diseases like rheumatoid arthritis and a large unmet medical need remains.'

  

See more

You may also like

Research & Development

Debiopharm pushes the boundaries of innovation in antibiotic development against gonorrhoea

Read more
First participant dosed with Debiopharm’s Debio 1453, a new drug candidate to address the high unmet need of multidrug-resistant infections with Neisseria gonorrhoeae

Trending Articles

  1. Continuous innovation: redefining the future of pharmaceutical manufacturing In an industry in which reliability is paramount and change can be slow, GEA has consistently proven that innovation and stability go hand in hand. Almost two decades ago, GEA introduced the first ConsiGma® continuous manufacturing (CM) system to the pharmaceutical market — a pioneering move that helped to reshape how oral solid dosage (OSD) forms are developed and produced
  2. Abselion launches AAVX and AAV9 Total Capsid Quantification Kits Ready-to-use solution for Amperia benchtop platform supports rapid, reliable quantification across a range of serotypes
  3. diaago and Peak Analysis & Automation partner to bring practical automation solutions to research laboratories Using diaago's customer-first approach with PAA’s decades of expertise in laboratory robotics, the collaboration promises to deliver solutions to streamline workflows, boost throughput and reduce bottlenecks
  4. Suncombe and Kindeva collaborate to deliver low-carbon inhalers to the NHS The partnership will develop next-generation pressurised metered-dose inhalers with low Global Warming Potential propellants, helping the NHS move closer to its Net Zero target
  5. Douglas Pharmaceuticals sets new benchmark for capsule quality with CI Precision Partnership delivers compliance confidence, efficiency gains and reduced waste

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Research & Development

Debiopharm pushes the boundaries of innovation in antibiotic development against gonorrhoea

First participant dosed with Debiopharm’s Debio 1453, a new drug candidate to address the high unmet need of multidrug-resistant infections with Neisseria gonorrhoeae
Manufacturing

Novacyt partners with Genepoc to diagnose respiratory infections

An international specialist in clinical diagnostics has entered into a clinical assay development contract with a Canadian company, which specialises in the development and manufacture of molecular diagnostic devices for the detection of infectious diseases
Research & Development

Debiopharm continues fight against antibiotic resistance

Debiopharm Group invests in antibiotic development with the acquisition of a minority stake in ABAC Therapeutics
Research & Development

Debiopharm acquires FibroTrap sample processing technology from Spinomix

Fibrinogen-based technology allows the highly specific separation and efficient concentration of target molecules from liquid samples
Research & Development

Debiopharm and Nobelex Biotech to develop antibiotics against N. Gonorrhoeae and enteric species

Initiated from Affinium technology platform
Research & Development

Evotec and Debiopharm to collaborate on development of new cancer treatment

The two companies will share discovery and development efforts
Manufacturing

Debiopharm aims to expand activities at its manufacturing facility in Martigny, Switzerland

Interested parties with appropriate projects should contact the company
Subscribe now